{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T18:50:55Z","timestamp":1783363855461,"version":"3.54.6"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1R03CA178118-01A1"],"award-info":[{"award-number":["1R03CA178118-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1K08CA230179-01"],"award-info":[{"award-number":["1K08CA230179-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000183","name":"United States Department of Defense | United States Army | U.S. Army Research, Development and Engineering Command | Army Research Office","doi-asserted-by":"publisher","award":["W81XWH1810236"],"award-info":[{"award-number":["W81XWH1810236"]}],"id":[{"id":"10.13039\/100000183","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001545","name":"Children's Tumor Foundation","doi-asserted-by":"publisher","award":["2016A-05-008"],"award-info":[{"award-number":["2016A-05-008"]}],"id":[{"id":"10.13039\/100001545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1038\/s41434-019-0080-9","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T16:05:52Z","timestamp":1558713952000},"page":"277-286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors"],"prefix":"10.1038","volume":"26","author":[{"given":"Ren-Yuan","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada J.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Riggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Wade Clapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Staedtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,24]]},"reference":[{"key":"80_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1749-6632.1986.tb48061.x","volume":"486","author":"JC Carey","year":"1986","unstructured":"Carey JC, Baty BJ, Johnson JP, Morrison T, Skolnick M, Kivlin J. The genetic aspects of neurofibromatosis. Ann N Y Acad Sci. 1986;486:45\u201356.","journal-title":"Ann N Y Acad Sci"},{"key":"80_CR2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s13311-017-0518-y","volume":"14","author":"V Staedtke","year":"2017","unstructured":"Staedtke V, Bai RY, Blakeley JO. Cancer of the peripheral nerve in neurofibromatosis type 1. Neurotherapeutics. 2017;14:298\u2013306.","journal-title":"Neurotherapeutics"},{"key":"80_CR3","first-page":"297","volume":"18","author":"A Abramowicz","year":"2014","unstructured":"Abramowicz A, Gos M. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease. Dev Period Med. 2014;18:297\u2013306.","journal-title":"Dev Period Med"},{"key":"80_CR4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrc3911","volume":"15","author":"N Ratner","year":"2015","unstructured":"Ratner N, Miller SJ. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer. 2015;15:290\u2013301.","journal-title":"Nat Rev Cancer"},{"key":"80_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1215\/15228517-2008-011","volume":"10","author":"VF Mautner","year":"2008","unstructured":"Mautner VF, Asuagbor FA, Dombi E, Funsterer C, Kluwe L, Wenzel R, et al. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro Oncol. 2008;10:593\u20138.","journal-title":"Neuro Oncol"},{"key":"80_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature13561","volume":"514","author":"T De Raedt","year":"2014","unstructured":"De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014;514:247\u201351.","journal-title":"Nature"},{"key":"80_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00401-012-0954-z","volume":"123","author":"FJ Rodriguez","year":"2012","unstructured":"Rodriguez FJ, Folpe AL, Giannini C, Perry A. Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. 2012;123:295\u2013319.","journal-title":"Acta Neuropathol"},{"key":"80_CR8","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1097\/SLA.0b013e3181a77e9a","volume":"249","author":"C Zou","year":"2009","unstructured":"Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang WL, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg. 2009;249:1014\u201322.","journal-title":"Ann Surg"},{"key":"80_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","volume":"39","author":"DG Evans","year":"2002","unstructured":"Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39:311\u20134.","journal-title":"J Med Genet"},{"key":"80_CR10","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1089\/hum.2017.167","volume":"28","author":"AC Nathwani","year":"2017","unstructured":"Nathwani AC, Davidoff AM, Tuddenham EGD. Advances in Gene Therapy for Hemophilia. Hum Gene Ther. 2017;28:1004\u201312.","journal-title":"Hum Gene Ther"},{"key":"80_CR11","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1080\/14712598.2017.1347630","volume":"17","author":"WB Guggino","year":"2017","unstructured":"Patel U, Boucher M, de L\u00e9s\u00e9leuc L, Visintini S. Voretigene neparvovec: an emerging gene therapy for the treatment of inherited blindness. CADTH issues in emerging health technologies. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016;169.","journal-title":"Expert Opin Biol Ther"},{"key":"80_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nrd.2018.110","volume":"17","author":"BE Deverman","year":"2018","unstructured":"Deverman BE, Ravina BM, Bankiewicz KS, Paul SM, Sah DWY. Gene therapy for neurological disorders: progress and prospects. Nat Rev Drug Discov. 2018;17:641\u201359.","journal-title":"Nat Rev Drug Discov"},{"key":"80_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.coph.2015.07.006","volume":"24","author":"L Lisowski","year":"2015","unstructured":"Lisowski L, Tay SS, Alexander IE. Adeno-associated virus serotypes for gene therapeutics. Curr Opin Pharmacol. 2015;24:59\u201367.","journal-title":"Curr Opin Pharmacol"},{"key":"80_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrg3742","volume":"15","author":"MA Kotterman","year":"2014","unstructured":"Kotterman MA, Schaffer DV. Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet. 2014;15:445\u201351.","journal-title":"Nat Rev Genet"},{"key":"80_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature15818","volume":"526","author":"L Naldini","year":"2015","unstructured":"Naldini L. Gene therapy returns to centre stage. Nature. 2015;526:351\u201360.","journal-title":"Nature"},{"key":"80_CR16","doi-asserted-by":"publisher","first-page":"7240","DOI":"10.1074\/jbc.M009202200","volume":"276","author":"KK Hiatt","year":"2001","unstructured":"Hiatt KK, Ingram DA, Zhang Y, Bollag G, Clapp DW. Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1-\/- cells. J Biol Chem. 2001;276:7240\u20135.","journal-title":"J Biol Chem"},{"key":"80_CR17","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1523\/JNEUROSCI.4693-04.2005","volume":"25","author":"B Dasgupta","year":"2005","unstructured":"Dasgupta B, Gutmann DH. Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J Neurosci. 2005;25:5584\u201394.","journal-title":"J Neurosci"},{"key":"80_CR18","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1128\/MCB.16.5.2496","volume":"16","author":"P Morcos","year":"1996","unstructured":"Morcos P, Thapar N, Tusneem N, Stacey D, Tamanoi F. Identification of neurofibromin mutants that exhibit allele specificity or increased Ras affinity resulting in suppression of activated ras alleles. Mol Cell Biol. 1996;16:2496\u2013503.","journal-title":"Mol Cell Biol"},{"key":"80_CR19","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/neuonc\/nor077","volume":"13","author":"RY Bai","year":"2011","unstructured":"Bai RY, Staedtke V, Aprhys CM, Gallia GL, Riggins GJ. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol. 2011;13:974\u201382.","journal-title":"Neuro Oncol"},{"key":"80_CR20","doi-asserted-by":"publisher","first-page":"6951","DOI":"10.1128\/MCB.18.12.6951","volume":"18","author":"RY Bai","year":"1998","unstructured":"Bai RY, Dieter P, Peschel C, Morris SW, Duyster J. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol. 1998;18:6951\u201361.","journal-title":"Mol Cell Biol"},{"key":"80_CR21","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1128\/MCB.01153-08","volume":"29","author":"V Bodempudi","year":"2009","unstructured":"Bodempudi V, Yamoutpoor F, Pan W, Dudek AZ, Esfandyari T, Piedra M, et al. Ral overactivation in malignant peripheral nerve sheath tumors. Mol Cell Biol. 2009;29:3964\u201374.","journal-title":"Mol Cell Biol"},{"key":"80_CR22","doi-asserted-by":"publisher","first-page":"e57152","DOI":"10.1371\/journal.pone.0057152","volume":"8","author":"DE Reuss","year":"2013","unstructured":"Reuss DE, Mucha J, Hagenlocher C, Ehemann V, Kluwe L, Mautner V, et al. Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC\/MAD and is potentiated by curcumin through induction of ROS. PLoS ONE. 2013;8:e57152.","journal-title":"PLoS ONE"},{"key":"80_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4137\/TOG.S8830","volume":"5","author":"D Sun","year":"2012","unstructured":"Sun D, Tainsky MA, Haddad R. Oncogene mutation survey in MPNST cell lines enhances the dominant role of hyperactive Ras in NF1 associated pro-survival and malignancy. Transl Oncogenomics. 2012;5:1\u20137.","journal-title":"Transl Oncogenomics"},{"key":"80_CR24","doi-asserted-by":"publisher","first-page":"11854","DOI":"10.1073\/pnas.182412299","volume":"99","author":"GP Gao","year":"2002","unstructured":"Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA. 2002;99:11854\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"80_CR25","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ymthe.2005.11.015","volume":"13","author":"CN Cearley","year":"2006","unstructured":"Cearley CN, Wolfe JH. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther. 2006;13:528\u201337.","journal-title":"Mol Ther"},{"key":"80_CR26","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/mt.2008.166","volume":"16","author":"CN Cearley","year":"2008","unstructured":"Cearley CN, Vandenberghe LH, Parente MK, Carnish ER, Wilson JM, Wolfe JH. Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol Ther. 2008;16:1710\u20138.","journal-title":"Mol Ther"},{"key":"80_CR27","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/jgm.1402","volume":"11","author":"LE Mays","year":"2009","unstructured":"Mays LE, Wilson JM. Identification of the murine AAVrh32.33 capsid-specific CD8+T cell epitopes. J Gene Med. 2009;11:1095\u2013102.","journal-title":"J Gene Med"},{"key":"80_CR28","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1128\/JVI.00254-08","volume":"82","author":"D Grimm","year":"2008","unstructured":"Grimm D, Lee JS, Wang L, Desai T, Akache B, Storm TA, et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol. 2008;82:5887\u2013911.","journal-title":"J Virol"},{"key":"80_CR29","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/sj.gt.3302133","volume":"10","author":"Z Wang","year":"2003","unstructured":"Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther. 2003;10:2105\u201311.","journal-title":"Gene Ther"},{"key":"80_CR30","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.1068452","volume":"296","author":"Y Zhu","year":"2002","unstructured":"Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science. 2002;296:920\u20132.","journal-title":"Science"},{"key":"80_CR31","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.1002\/j.1460-2075.1991.tb04979.x","volume":"10","author":"JF Hancock","year":"1991","unstructured":"Hancock JF, Cadwallader K, Paterson H, Marshall CJ. A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins. EMBO J. 1991;10:4033\u20139.","journal-title":"EMBO J"},{"key":"80_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017;170:17\u201333.","journal-title":"Cell"},{"key":"80_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0092-8674(00)80607-8","volume":"98","author":"E Choy","year":"1999","unstructured":"Choy E, Chiu VK, Silletti J, Feoktistov M, Morimoto T, Michaelson D, et al. Endomembrane trafficking of ras: the CAAX motif targets proteins to the ER and Golgi. Cell. 1999;98:69\u201380.","journal-title":"Cell"},{"key":"80_CR34","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s11262-017-1502-7","volume":"53","author":"J Weinmann","year":"2017","unstructured":"Weinmann J, Grimm D. Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes. 2017;53:707\u201313.","journal-title":"Virus Genes"},{"key":"80_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12896-015-0230-0","volume":"16","author":"Y Mao","year":"2016","unstructured":"Mao Y, Wang X, Yan R, Hu W, Li A, Wang S, et al. Single point mutation in adeno-associated viral vectors -DJ capsid leads to improvement for gene delivery in vivo. BMC Biotechnol. 2016;16:1.","journal-title":"BMC Biotechnol"},{"key":"80_CR36","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/gt.2015.47","volume":"22","author":"SA Hoyng","year":"2015","unstructured":"Hoyng SA, De Winter F, Gnavi S, van Egmond L, Attwell CL, Tannemaat MR, et al. Gene delivery to rat and human Schwann cells and nerve segments: a comparison of AAV 1-9 and lentiviral vectors. Gene Ther. 2015;22:767\u201380.","journal-title":"Gene Ther"},{"key":"80_CR37","doi-asserted-by":"publisher","first-page":"a031500","DOI":"10.1101\/cshperspect.a031500","volume":"9","author":"K Scheffzek","year":"2018","unstructured":"Scheffzek K, Shivalingaiah G. Ras-Specific GTPase-Activating Proteins-Structures, Mechanisms, and Interactions. Cold Spring Harb Perspect Med. 2018;9:a031500.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"80_CR38","doi-asserted-by":"publisher","first-page":"16409","DOI":"10.1074\/jbc.271.27.16409","volume":"271","author":"MR Ahmadian","year":"1996","unstructured":"Ahmadian MR, Wiesmuller L, Lautwein A, Bischoff FR, Wittinghofer A. Structural differences in the minimal catalytic domains of the GTPase-activating proteins p120GAP and neurofibromin. J Biol Chem. 1996;271:16409\u201315.","journal-title":"J Biol Chem"},{"key":"80_CR39","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1093\/emboj\/17.15.4313","volume":"17","author":"K Scheffzek","year":"1998","unstructured":"Scheffzek K, Ahmadian MR, Wiesmuller L, Kabsch W, Stege P, Schmitz F, et al. Structural analysis of the GAP-related domain from neurofibromin and its implications. EMBO J. 1998;17:4313\u201327.","journal-title":"EMBO J"},{"key":"80_CR40","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1101\/gad.190876.112","volume":"26","author":"IB Stowe","year":"2012","unstructured":"Stowe IB, Mercado EL, Stowe TR, Bell EL, Oses-Prieto JA, Hernandez H, et al. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. Genes Dev. 2012;26:1421\u20136.","journal-title":"Genes Dev"},{"key":"80_CR41","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1074\/jbc.M115.703710","volume":"291","author":"Y Hirata","year":"2016","unstructured":"Hirata Y, Brems H, Suzuki M, Kanamori M, Okada M, Morita R, et al. Interaction between a domain of the negative regulator of the Ras-ERK pathway, SPRED1 protein, and the GTPase-activating protein-related domain of Neurofibromin is implicated in Legius Syndrome and neurofibromatosis type 1. J Biol Chem. 2016;291:3124\u201334.","journal-title":"J Biol Chem"},{"key":"80_CR42","doi-asserted-by":"publisher","first-page":"7497","DOI":"10.1073\/pnas.1607298113","volume":"113","author":"T Dunzendorfer-Matt","year":"2016","unstructured":"Dunzendorfer-Matt T, Mercado EL, Maly K, McCormick F, Scheffzek K. The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation. Proc Natl Acad Sci USA. 2016;113:7497\u2013502.","journal-title":"Proc Natl Acad Sci USA"},{"key":"80_CR43","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nmeth.3312","volume":"12","author":"A Chavez","year":"2015","unstructured":"Chavez A, Scheiman J, Vora S, Pruitt BW, Tuttle M, PRI E, et al. Highly efficient Cas9-mediated transcriptional programming. Nat Methods. 2015;12:326\u20138.","journal-title":"Nat Methods"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41434-019-0080-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41434-019-0080-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41434-019-0080-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:13:59Z","timestamp":1684617239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-019-0080-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,24]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["80"],"URL":"https:\/\/doi.org\/10.1038\/s41434-019-0080-9","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,24]]},"assertion":[{"value":"9 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A provisional patent application on Rasopathy treatment listing R.Y.B. and V.S. as co-inventors was filed by JHU.\u00a0D.E., A.J.T., G.J.R., D.W.C. and F.M. have no conflicts of interest to declare.\u00a0\u00a0","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}